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Background and aims: DNA damage and mitochondrial dysfunction are thought to play an essential role
in ageing and the energetic decline of vascular smooth muscle cells (VSMCs) essential for maintaining
plaque integrity. We aimed to better understand VSMCs and identify potentially useful compensatory
pathways that could extend their lifespan. Moreover, we wanted to assess if defects in mitochondrial
respiration exist in human atherosclerotic plaques and to identify the appropriate markers that may
reﬂect a switch in VSMC energy metabolism.
Methods: Human plaque tissue and cells were assessed for composition and evidence of DNA damage,
repair capacity and mitochondrial dysfunction. Fresh plaque tissue was evaluated using high resolution
oxygen respirometry to assess oxidative metabolism. Recruitment and processing of the mitochondrial
regulator of autophagy Pink1 kinase was investigated in combination with transcriptional and protein
markers associated with a potential switch to a more glycolytic metabolism.
Results: Human VSMC have increased nuclear (nDNA) and mitochondrial (mtDNA) damage and reduced
repair capacity. A subset of VSMCs within plaque cap had decreased oxidative phosphorylation and
expression of Pink1 kinase. Plaque cells demonstrated increased glycolytic activity in response to loss of
mitochondrial function. A potential compensatory glycolytic program may act as energetic switch via
AMP kinase (AMPK) and hexokinase 2 (Hex2).
Conclusions: We have identiﬁed a subset of plaque VSMCs required for plaque stability that have
increased mitochondrial dysfunction and decreased oxidative phosphorylation. Pink1 kinase may initiate
a cellular response to promote a compensatory glycolytic program associated with upregulation of AMPK
and Hex2.
© 2017 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Human atherosclerotic plaques are ﬁbro-fatty arterial wall le-
sions which frequently rupture into the circulation and arguably
are responsible for the majority of heart attacks and strokes. Risk
factors such as inactivity, smoking and elevated cholesterol and
lipid intake, generates a systemic inﬂammatory response that
drives arterial wall and plaque inﬂammation [1]. Vascular smooth
muscle cells (VSMC) are the main, synthetic and structuralmuscle; OXPHOS, oxidative
ercer).
Ireland Ltd. This is an open accesscomponent of the vessel wall and plaque [2]. In response to injury
during atherogenesis VSMC will transdifferentiate from contractile
to a synthetic phenotype [3]. While VSMC's normally proliferate
slowly in the plaque they also appear to have completed more cell
divisions as evidenced by their decreased telomere length [4]
which initiates a DNA damage response [5]. It is predicted that
this need to proliferate and repair generates an ATP (adenosine
triphosphate) demand and excess reactive species (RS) and oxygen
free radicals that drives further DNA damage, genomic instability
and mitochondrial dysfunction [6e8]. We predict that these char-
acteristics accelerate atherosclerotic plaque formation and then
limit VSMCs regenerative capacity [9,10]. Indeed, additional radi-
cals produced through vessel wall NADPH oxidase complexes also
promotes endothelial dysfunction [11] and hypertension [12]article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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Table 1
Compositional analysis of intra-atherosclerotic plaque from human carotid endar-
terectomy specimens.
Wall Shoulder Cap Core
Cell density
1.0xE5/mM2
81.9 ± 6.2 146 ± 20.7 91.3 ± 13.2 32.8 ± 6.4
VSMC (%) 99.4 ± 0.5 90.9 ± 5.0 94.1 ± 1.9 41.9 ± 11.2
Macrophages (%) 1.9 ± 0.6 48.0 ± 9.8 1.6 ± 0.3 21.7 ± 4.9
C.K. Docherty et al. / Atherosclerosis 268 (2018) 1e11 3which are known to initiate and exacerbate the progression of
cardiovascular disease.
Mitochondria are the electrochemical batteries of the cell. Not
only are they a source of ATP, they also buffer calcium beyond the
traditional role of the endoplasmic reticulum (ER) and are impor-
tant in initiating the intrinsic apoptosis cascade through caspase
activation [13]. While the mitochondria retain a small 16 Kb
genome, they lack the high ﬁdelity repair systems of the nucleus.
This property leaves the mitochondria vulnerable to the accumu-
lation of damage which results in the loss of the proton motive
gradient that drives the mitochondrial membrane potential (DJm)
required for ATP production and cell viability [14].
Pink-1 is the nuclear encoded protein kinase that under normal
circumstances is constitutively synthesised in the cytoplasm and
recruited to the outer mitochondrial membrane (OMM) where its
mitochondrial targeting sequence (MTS) is cleaved. It is processed
through the inner mitochondrial membrane (IMM) surface by the
Presenilins-associated rhomboid-like protein (PARL) and passes
through the mitochondrial outer membrane (TOM) complexes. In
the presence of a mitochondrial membrane potential (DJm),
which is required for energy production, it is further processed
through the translocases of the inner membrane (TIM) for retro-
grade transport out of the mitochondria [15] where it is then
degraded. However, when DJm is lost, Pink-1 becomes trapped at
the outer mitochondrial membrane and ﬂags the organelle as
defective [16]. The ubiquitin ligase Parkin is recruited, binds Pink-1
[17] and orchestrates organelle recycling through the proteosomal
degradation and engulfment [18]. This phenomenon of Pink-1 as
mitochondrial biosensor is important and has not been investi-
gated before in atherosclerotic plaques and VSMCs. If Pink-1 could
also augment alternative energy pathways, than in the future
pharmacologically switching VSMC energetics early in disease may
offer a potential therapy.
We predict that during plaque formation VSMC mitochondria
accumulate DNA damage leading to loss of DJm.We predict Pink-1
will accumulate and become trapped at the outer mitochondrial
membrane, resulting in oxidative energetic dysfunction. If Pink1 is
present in human plaque VSMCs, it could be an important marker
in detecting the failing cellular energetics of the plaque cap cells.
This may allow recapitulation of the human plaque cell phenotype
by transgenic manipulation of Pink-1 expression. An appropriate
in vivo model could then function as a testbed for identifying
alternative energy pathways and compounds that can activate
energetic switching at earlier time-points during disease that could
rescue p-VSMC phenotype.
To explore these ideas, we ﬁrst investigated the energetic
decline in plaque VSMC in response to nuclear and mitochondrial
DNA damage and then the importance of Pink-1 in VSMC energy
balance through potentially augmenting compensatory glycolytic
pathways.
2. Materials and methods
2.1. Microdissection
Human carotid atherectomy specimens were obtained through
the NHSCGC Biorepository and Pathology Services REC 10/S20704/
60 after local ethical and patient approval. Each fresh sample was
serially dissected, one piece used for histology, one for explant cellFig. 1. Human carotid plaque composition; VSMC and macrophage regional abundance.
(A) Carotid plaque cross section; thin ﬁbrous cap, core removed en bloc; adventitial wall dis
and cap. (B) Plaque histology for smooth muscle stained (a-SMA) carotid plaque, gross morph
(C) a-SMA þ VSMCs. (D) Mac-3 þ monocyte/macrophages (scale bar 100 mm). (E) Cell abund
(High power 20X, low power 4X).culture of wall VSMC nearest the plaque, one portion banked for
RNA/DNA/protein extraction and the ﬁnal portion used for oxygen
respiration studies. For the respiration studies, the allotted piece
was sub-divided into the wall; the VSMC rich residual adventitial
and medial component of the artery, the core which contains the
lipid rich inﬂammatory gruel, the shoulder which is rich in mitotic
VSMCs and links the wall to the cap, and the cap, which is the often
a thin overlaying VSMC sheet that maintains the plaque in situ and
the site of rupture in the plaque. Plaques were imaged using Veho
micro-capture v1.3. Primary VSMCs were cultured from explanted
carotid specimens and identiﬁed by immunocytochemistry for a-
smooth muscle cell actin (SMA) myosin heave chain (MHC) and
Calponin as previously described [4,19].
2.2. DNA damage assays
As previously described [20], DNA damage assays were per-
formed in chamber-slides (Ibidi) cultured with primary explant
VSMCs. Using immunoﬂuorescence for detection, cells were ﬁxed
in ice cold methanol (10 min), blocked with 3% BSA/PBS, and pro-
bed with p-ATMser1981 (red channel) and p-H2AXser 15 (green
channel) 1 h (Cell Signaling) and 30 min for ﬂuorescent secondary
antibodies (Cell signaling), using an isotype primary negative
control and secondary. Total foci for both markers were scored per
cell. Micronuclei were counterstained with biz-benzimide (blue
channel) (Sigma). COMET assay was performed on slides in which
isolated nuclei were derived from a cell alkaline lysis buffer and
embedded in lowmelting point agarose with a 2% agarose support.
Slides were electrophoresed at 1 V/cm for 10e20 min, then coun-
terstained with ethidium bromide and scored. mtDNA PCR was
performed as previously described [10].
2.3. Immunostaining assays
Pink-1 was assessed using an antiPink1 (Abcam 117091) raised
to a synthetic peptide made to human PINK1 protein (residues
175e250). VSMC mitochondrial network was assessed by staining
for the importer receptor-translocase of outer membrane (TOM20 -
Ab56783). Cells were ﬁxed in ice-cold methanol and blocked in 3%
bovine serum albumin (BSA) and counterstained with Hoechst
(H33342). (Zeiss, LSM 510). Mitopainter was added to visualise the
coupled mitochondrial membrane potential, and uncoupling ach-
ieved through addition of CCCP (1e10 mM, Sigma). An IgG isotype
and secondary antibody was used to control for non-speciﬁc
binding.
2.4. Polargraphic whole tissue oxygen respirometry:O2K
Fresh biopsies of human tissues were obtained under localsected away from overlying structures with the shoulder region a mixture of wall, core
ology identifying each of the regions of interest: (i) wall, (ii) shoulder, (iii) cap, (iv) core.
ance in plaque regions (n ¼ 7) and results quantiﬁed. (F) Histology of Pink expression
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carotid endarterectomy procedures. Brieﬂy, tissue was washed in
BIOPS pH 7.1 and permeabilised with saponin (5 mg/ml). Samples
were further washed 3  5 min in BIOPS before paired tissue
samples (~10 mg w/w) were added to the respirometry chambers
(Oroboros Instruments, Innsbruck). Complex 1 respiration was
stimulated with glutamate and malate and ADP before inhibition
with rotenone to reveal a complex 1 dependent oxygen con-
sumption rate (OCR). Stimulation of complex 2 dependent respi-
ration was made by addition of the complex 2 substrate succinate
and then inhibited by antimycin. Complex 4 respiration was stim-
ulated with the electron donor ascorbate and artiﬁcial complex 4
substrate TMPD (N,N,N0,N0-Tetramethyl-p-phenyl-
enediaminedihydrochloride). A ﬁnal addition of excess cytochrome
C showed no further increase in respiration, and conﬁrmed the
integrity of the respiratory chain preparation. All rates were nor-
malised to dry tissue mass and immunohistology conﬁrmed cell
type and cell density for each region by eosin and haematoxylin
(H&E) staining.
2.5. RNA extraction and real-time qPCR
Carotid arteries were selected based on their en face properties
from our biobank of 40 samples (age range 50e76 years, with both
sexes represented). Specimens were dissected into four areas: cap,
core, shoulder and wall. Each area was ﬁnely minced using a sterile
scalpel and placed into QIAzol solution. Stainless steel beads were
added and samples were lysed using a TissueLyser (™) (Qiagen).
Proteinase K (ﬁnal concentration 100 mg/ml) was added to the
QIAzol solution and incubated at 56 C for 1 h. Samples were then
placed back into the tissue lyser to fully disrupt the remaining
tissue fragments. RNA species were then extracted with miRNeasy®
mini kit (Qiagen), quantiﬁed using a nanodrop spectrophotometer
and normalised. RNA was then reversetranscribed to cDNA using
the TaqMan® reverse transcription kit (Applied Biosystems). Real-
time PCR was performed using the Applied Biosystems 7900 HT
real-time PCR system, following manufacturer's instructions. Spe-
ciﬁc TaqMan® primer-probes were purchased from Life-
technologies (Supplementary Table 1).
2.6. Microscopy
Bright ﬁeld, confocal and time-lapse microscopy was under-
taken as previously described, [20].
2.7. Western blotting
Carotid artery smooth muscle cells grown from carotid artery
wall explants were grown in 6-well plates. 80e90% conﬂuent cells
were washed in PBS and lysed in 1% Lauryl maltoside detergent
(Abcam)/PBS plus protease inhibitor cocktail (Sigma), scraped and
sonicated. Twenty mg of protein lysates was fractionated on 4e12%
gradient polyacrylamide gels and transferred to nitrocellulose
membranes (Amersham). Membranes were then blocked in 1:1
Seablock (Thermoﬁsher) and 1:1 Tris-buffered saline plus tween 20
(TBS/T). Membraneswere incubated overnight at 4 Cwith relevant
primary antibody (Supplementary Table 2). Membranes were then
washed in TBS/T and incubated with ﬂuorescent secondaryFig. 2. Human carotid plaque tissues have increased nuclear and mitochondrial DNA dama
(A) DNA damage foci from control VSMC plaque cells ± hydrogen peroxide (t-BHP) treatm
VSMC ± t-BHP (n ¼ 4). (C) Nuclear DNA micronuclei in control and plaque VSMC ± t-BHP
plaque tissue oxygen respiration for key regions (n ¼ 7). (F) Tissue oxygen consumption rate
for Complex 2 dependent respiration (n ¼ 7). (H) Tissue oxygen consumption rate (OCR) fo
Whitney U-test *p ¼ 0.05).antibody (Life technologies; 1:15000) for 2 h. Membranes were
then transferred to the LI-COR Odyssey infrared imaging system for
visualisation. Densitometric analysis was then performed on LI-
COR image studio light (version 5.2).
2.8. Glucose uptake assay
A luciferase based 2 deoxyglucose assay was performed using
human plaque VSMCs (Promega J1341). Brieﬂy, cells were stimu-
lated and quiesced in a zero glucosemedia. 2-deoxy glucose (1mM)
was pulse incubated with the cultures using a 96-well plate format
for ~10 min. Cells were then lysed and neutralized before a custom
lucigenic reaction mixture was added. Luminescence was then
recorded using a 0.3 integration interval on a VICTOR, Perkin Elmer
multi-label plate reader.
2.9. XF24 extracellular ﬂux analysis
As previously described [20], 000 cells were plated into a Sea-
horse 24-well culture plate 24 h prior to the assay. These were then
washed and quiesced with Seahorse low glucose buffered media.
Using a 2-2-2 min (Mix-Wait-Measure) protocol, a pre-calibrated
sensor plate was preloaded with 100 ml of Oligomycin (1 mM) port
A, CCCP (1 mM) Port B and Rotenone and antimycin (1 mMeach) Port
C&D. The platewas pre-incubated andwarmed at 37 C. At the end
of the assay, reference wells were taken for protein determination
and equal cell loading.
2.10. Histology
Histology was performed as previously described [19e21,10].
Goat anti-rabbit HRP secondary antibodies (A6154, Sigma) and
Vector labs DAB secondary HRP staining kit (SK4100) were used for
staining, including a secondary negative control and an inﬁltrating
breast ductal carcinoma used as positive control (AMSBIO ™
CU2005/17).
2.11. Statistical analysis
All data are presented as mean ± standard error of the mean
(SEM), where appropriate. p values were calculated using Student's
unpaired t-tests (two-tailed distribution). Statistical signiﬁcance
was considered as p < 0.05 (one star), p < 0.01 (two stars) or
p < 0.001 (three stars). All analysis was performed on Microsoft
Ofﬁce Excel 2007 or Graph pad Prism (v 5). All graphs were pro-
duced on MS Excel or Graph pad Prism (v 5). One-way analysis of
variance (ANOVA) was used to determine signiﬁcant difference
between two or more independent groups.
3. Results
3.1. Human plaque microdissection and phenotyping
To determine the role of mitochondria in regulating the ener-
getic phenotype of the plaque, we generated a biobank of human
carotid endarterectomy plaque samples. From 60 samples, we
micro-dissected those plaques with the en face properties that
clearly showed the four identiﬁable regions of cap, core, shoulderge and defects in oxidative phosphorylation.
ent (n ¼ 4). (B) Nuclear repair assessed through COMET assay for control and plaque
(n ¼ 4). (D) Mitochondrial DNA damage in control and plaque VSMC (n ¼ 7). (E) Total
(OCR) for Complex 1 dependent respiration (n ¼ 7). (G) Tissue oxygen consumption rate
r Complex 4 dependent respiration (n ¼ 7) (non-binomial distribution tested by Mann
Fig. 3. Mitochondria abundance and Pink1 expression in human plaque cells and tissues.
(A) Pink-1 mRNA expression in isolated plaque tissue using real-time Taqman DDCt, normalised to citrate synthase, (i) citrate synthase mRNA expression (n ¼ 5), (ii) mitofusin
expression (n ¼ 5). (B) Confocal immunocytochemistry of Pink1 protein in isolated plaque cells after uncoupling. (i) Anti Pink1 Ab mitochondrial staining. (ii) Network changes after
uncoupling with CCCP (1 mM). (iii) Secondary only control. (iv) Anti-TOM20 organelle staining. (v) Anti-TOM20 after uncoupling. (vi) Secondary IgG antibody control, (vii) with
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stained and scored for cell type and density (Fig. 1B). In partic-
ular, for the two most important types that determine plaque fate:
VSMC and monocyte/macrophages. A reﬁnement of previous work
showed the plaque cap likely had a similar cell density to the wall,
with the majority of these cells being either smooth muscle actin
(SMAþ) (Fig. 1C) and/or Myosin Heavy Chain (MHCþ)
(Supplementary Fig. 1) positive cells. Less than 2% of cells being
inﬁltrating immune cells, such as mac3þ monocyte/macrophages
(Fig. 1D). In contrast, the plaque shoulder region appeared as the
most dynamic region, with almost twice the density cells and a
much higher proportion of inﬁltrating macrophages, which was
quantiﬁed (Fig. 1E) and tabulated (Table 1). While the largely
acellular lipid core had the lowest cell density, the plaque shoulder
had the highest one, with the combined scoring in some regions
suggesting greater than 100% of marked cells, possibly from anti-
genic debris left over from apoptosis and necrosis. To assess plaques
for markers of mitochondrial dysfunction where oxidative meta-
bolism was compromised, we immuno-stained for Pink-1 kinase.
Pink-1 expression was increased in the plaque cap region vs. the
control. (Fig. 1F).3.2. DNA damage and mitochondrial dysfunction in plaques
From our human carotid plaques tissue samples, we generated
explanted primary human VSMCs using fresh medial portions
derived from patient's undergoing carotid atherectomy (approved
NHS GC&C Biorepository application 107 REC 10/S20704/60). These
primary cell lines were also routinely immuno-stained and
conﬁrmed as expressing a-SMA and myosin heavy chain
(Supplementary Fig. 1), and additional VSMC markers, including
vimentin and calponin. We then immuno-stained the derived cells
for their nuclear DNA damage foci, combing expression of p-ATM
and p-H2AX foci/cell (Cell signaling, UK) in the presence and
absence of the hydrogen peroxide analogue, t-BHP (Sigma, UK)
(Fig. 2A). In addition, we scored their DNA repair capacity (Fig. 2B)
using the COMET assay (Comet Assay IV™) and unrepaired DNA as
extruded as micronuclei (Fig. 2C). Using a semi-quantitative PCR
method that compared ampliﬁcation efﬁciency between a large
10 Kb and a small 250 bp sequence of the mitochondrial genome,
the number of lesions 10 Kbwas determined (Fig. 2D). To assess the
functional impact of this across the plaque, fresh sub-plaque re-
gions were micro-dissected and assessed for oxygen consumption
and the total contribution of each respiratory complex was deter-
mined. Respiration was consistently decreased across the plaque
when compared to the wall region (Fig. 2EeH). In particular,
complexes 2 and 4 respiration were signiﬁcantly compromised
(Fig. 2G and H).3.3. Pink-1 ﬂags dysfunction plaque cap tissue and cells
To determine the mechanism by which oxidative phosphoryla-
tion may be compromised, we assessed the abundance of key
mRNA transcripts associated with mitochondrial health in VSMCs.
We found a signiﬁcant upregulation of Pink 1 kinase mRNA
(Fig. 3A), corroborating our ﬁnding in plaque tissue. No difference
in plaque VSMC mitochondrial content was detected when using
the mRNA expression of the nuclear encoded Krebs cycle enzyme
citrate synthase (Fig. 3Aei) or the mRNA expression of the
mitophagy regulator MFN2 (Fig. 3Aeii). The subcellular VSMClocalisation, (viii) and after uncoupling. (C) Quantiﬁcation of Pink1 and Tom20 localisation
pling with CCCP. (D) Western blot of phospho and total AMPK abundance and before and afte
tubulin. (E) Quantiﬁcation of p-AMPK protein expression. (ANOVA * p ¼ 0.05).localisation of Pink1 protein relative to a mitochondrial protein
marker TOM20 was determined using confocal microscopy
(Fig. 3B). After uncoupling DJm with the respiratory chain un-
coupler CCCP (1 mM), Pink1 levels stabilised and were co-localised
with TOM20 on the mitochondrial membrane, observed as a shift
from green (vii) to yellow staining (viii), and this effect could also be
quantiﬁed using the non-potentiometric dye mitopainter™
(Fig. 3C).
Loss of oxidative metabolism is predicted to decrease abun-
dance of the adenosine triphosphate (ATP) and increase the energy
sensor AMP kinase (AMPK). To assess this aspect, isolated VSMCs
were stimulated with either hydrogen peroxide (t-BHP) or uncou-
pler (CCCP), to mimic mitochondria dysfunction. Western blotting
assessed total and phospho-AMPK and phospho-Pink1 protein
expression during mitochondria recruitment, processing and acti-
vation. While hydrogen peroxide could increase total Pink1 protein
(65 KDa) at both low and high concentrations, the active 55 kDa
Pink1 accumulated only after uncoupling with CCCP. This
conﬁrmed the uncoupling as essential for Pink-1 activation in
VSMCs, associated with a concomitant increase in the energy
sensor AMPK (Fig. 3D). This effect was greatest after 24 h stimu-
lation and was quantiﬁed (Fig. 3E), and was also observed after
incubation with a vascular relevant stressor, oxidised LDL
(Supplementary Figs. 1E and F).3.4. Plaque transcript analysis
Interacting factors that could augment Pink1 were explored
using MetaCore™ network analysis. This identiﬁed a number of
potential proteins; using real-time qPCR expression analysis, we
validated potential targets.We found no changes in the constitutive
expression of either HIF-1alpha or its regulatory prolyl hydroxylase
P4H (PHD1) (Fig. 4A and B).
We did identify elevated hexokinase II transcripts in the cap, the
ﬁrst enzyme of the glycolytic pathway (Fig. 4C). In addition, pyru-
vate dehydrogenase kinase (PDK) the regulator of PDH activity, the
enzyme responsible for converting pyruvate to acetyl CoA, was also
elevated, however, it was not statistically signiﬁcant (Fig. 4D). To
test if plaque-derived cells had an altered capacity to increase
glycolysis, we measured glucose uptake using a non-radioactive
bioluminescent method based on uptake of 2-deoxyglucose-6-
phosphate (2DG6P) (Promega-Glucose UptakeGlo). We found
plaque-derived cells had increased uptake in the presence of
absence of the DNA damaging agent t-BHP (Fig. 4E). We further
tested the ability of plaque cells to maintain glycolysis during res-
piratory uncoupling using the Seahorse XF24 bioanalyser. The XF24
measures extracellular acidiﬁcation caused by protons (Hþ ions)
generated during catabolism of glucose to lactate, but also the
release of carbon dioxide during glucose oxidation. When
comparing carotid plaque VSMC with control aortic VSMCs, we
found a signiﬁcant (p ¼ 0.001) and sustained increase in ECAR
(Fig. 4F). To validate these changes, we also assessed human plaque
tissue for their protein abundance for glycolytic and TCA proteins
such as PDK (Fig. 5). The abundance of GAPDH, LDH, PDK and Hex
was all signiﬁcantly increased in the plaque cap compared to the
wall (Fig. 5A and B) and levels were further quantiﬁed (Fig. 5C). To
try and understand the implications of these changes in the plaque,
we assessed isolated plaque cells response to genotoxic stress.
Using time-lapse microscopy, over 48 h, we found plaque cells
proliferated more slowly and underwent apoptosis moreafter uncoupling using the non-potentiometric dye (mitopainter) and Pink-1 ± uncou-
r uncoupling with CCCP and the DNA damaging agent t-BHP (n ¼ 3) normalised to beta
Fig. 4. mRNA expression of regional plaque markers and glucose uptake in human plaque cells.
(A) Expression of plaque HIF-1a /18S DCt change in expression. (B) HIF-1a degrading prolyl hydroxylases (PHD)/18S. (C) Hexokinase II /18S expression. (D) Pyruvate dehydrogenase
kinase /18S (n ¼ 4e6). (E) Glucose uptake in aortic control and carotid plaque derived cells (n ¼ 2) (ANOVA * p ¼ 0.05). (F) Seahorse XF24 extracellular acidiﬁcation rate (ECAR) of
control and plaque VSMC during uncoupling with CCCP (1 mM). Student t-test (** *p ¼ 0.001) (n ¼ 3).
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Fig. 5. Comparison of glycolytic markers between carotid plaque wall and cap.
(A) Human carotid plaques were compared across whole plaque sections (low power 40 scale 500 mm) (i-vi). (B) High power comparisons made: (i) glyceraldehyde 3-phosphate
dehydrogenase (GAPDH), (ii) lactate dehydrogenase (LDH), (iii) pyruvate dehydrogenase kinase (PDK), (iv) pyruvate kinase muscle (PKM) isoenzyme 1/2, and (vi) hexokinase (HEXI/
II) (n ¼ 4). Including irrelevant IgG isotype and secondary negative control and a tumour positive control (AMSBIO) 400 (scale 100 mm). (C) Quantiﬁcation histogram of glycolytic
markers excluding nominal PDH expression, comparing between plaque cap and wall (n ¼ 3) (2 way ANOVA* p ¼ 0.05, **p ¼ 0.01, ***p ¼ 0.001).
C.K. Docherty et al. / Atherosclerosis 268 (2018) 1e11 9frequently, reﬂecting the terminal nature of these explanted cells
(Supplementary Fig. 2).
4. Discussion
The majority of cardiovascular related deaths are attributable to
atherosclerotic plaque rupture [22]. The thinning of the overlying
p-VSMC cap precipitates rupture and erosion and is likely respon-
sible for the majority of cardiovascular related-mortality from
myocardial infarctions and strokes.
The phenotype of the vascular smooth muscle cells that con-
stitutes the vessel wall and plaque has continued to be evaluated
over many years ([23e25]). Our previous work has investigated the
DNA damage response using transgenic models, but the physio-
logical and energetic responses of these cells in human diseased
samples remains to be explored. We now provide the implications
of this phenotype in human carotid plaques and a rationale for the
metabolic decline of plaque cells.
We identiﬁed the plaque cap cells in terminal decline, as
tentatively having an alternative bioenergetic proﬁle compared to
the vessel wall and neighbouring plaque structures. We have
shown that when co-stained with markers of VSMC content, the
cap likely contains no signiﬁcant difference in VSMC content
compared to the wall, although some “vulnerable regions” clearly
have fewer cells. More importantly, there appears to be a signiﬁcant
drop in cap tissue oxygen consumption, in particular during Com-
plex II and IV dependent respiration. Assessment of mitochondrialabundance identiﬁed normal plaque cap mitochondrial quantity
but at a reduced quality, and this was linked to the recruitment and
retention of Pink1. This process may promote induction of p-AMPK
as an energy sensor and induction of glycolytic enzymes such as
hexokinase 2 and mitochondrial PDH. PDH is important as it reg-
ulates the metabolic ﬂexibility between glycolysis and oxidative
metabolism. The implication of these data was supported by an
increased uptake of the glucose analogue 2-deoxy-glucose in iso-
lated plaque cells basally and after stress (t-BHP). Moreover,
plaque-derived VSMCs when assessed for glycolytic ﬂux, compared
to aortic controls, were also more glycolytic during uncoupling.
Increasing glycolysis would be predicted to restore ATP abundance,
at least when assessed in isolated cells. We predict this could be a
survival response to the energetic failure in the plaque cells and, if
invoked earlier in disease, could be a therapeutic strategy.
Our ability to demark energetic changes geographically within
the plaque sheds new light on how plaque tissue may respond
during development and rupture. Understanding how these
changes manifest as alterations in VSMC mitochondrial respiratory
chain complex activities, in particular Complex II and Complex IV
dependent respiration, is new. This work highlights the heteroge-
neity of regional cellular respiration within the plaque and how
plaque VSMCs respond to genotoxic stress. Further work is now
required to understand the temporal energetic demise of plaque
mitochondria and further substantiates the presence of a tentative
alternative energetic program in plaque VSMCs. If this program is
initiated by Pink1 kinase and dependent on hexokinase I/II, it could
C.K. Docherty et al. / Atherosclerosis 268 (2018) 1e1110be a useful starting point to intervene in these processes. Indeed, in
our cellular model, we found the energy sensor AMPK was also
upregulated in response to uncoupling and DNA damage, sug-
gesting the loss of ATP (when ADP/AMP is high) may be sufﬁcient to
trigger AMPK to restore glycolysis.
We report an almost 3-fold elevation in hexokinase II expression
in plaque cap specimens. Hexokinase II (Hex II) is the most abun-
dant isoform of the hexokinase family [26], and its elevated intra-
cellular activity is a crucial step in glycolysis, through
phosphorylation of glucose to glucose-6-phosphate [27]. Its abun-
dance has been positively correlated in plaque carotid specimens
with concomitant elevation of glucose transporters (Glut1-3) [28].
Hexokinase II is the only family member to associate with the outer
mitochondrial membrane and has previously been identiﬁed after a
genome-wide screen of small hairpin RNA, reported as critical for
the Pink1 dependent ubiquitin ligase Parkin to be recruited [29].
Hex II expression in the plaque cap may potentially drive the
proposed energetic switch through driving elevation of PDH ac-
tivity and block the pyruvate dehydrogenase complex (PDC) ac-
tivity required for oxidative metabolism, thereby favouring
glycolysis in response to mitochondrial dysfunction [30,31,20].
Note, that while hexokinase I is the predominate isoform in
humans, hexokinase II has a greater than 70% homology, but is
usually found in lower abundance.
These new insights provide a rationale to interrogate Pink1
binding partners in atherosclerosis and to discover if plaque VSMCs
can energetically switch from oxidative phosphorylation to
glycolysis earlier in atherogenesis. Pink-1 ablation could be used to
model the features of energetic dysfunction and develop the im-
plications of energetic switching further. Characterising these
changes during disease could be undertaken with a return to
appropriate inducible and lineage speciﬁc transgenic models of
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